Sector Investors News and Insights

VRTX

ETFsector.com Daily Trading Outlook

November 4, 2025 S&P futures -1.0% in early Tuesday trading after U.S. equities ended mixed Monday, with narrow breadth again the dominant theme — over 60% of S&P 500 components declined even as Big Tech outperformed on AI partnership headlines. Overseas markets are weaker: Asia saw sharp declines (South Korea -2.5%, Japan -1.7%) and Europe […]

ETFsector.com Daily Trading Outlook Read More »

, , , , , , , , , , , , , , , , , , , , , , , , ,

ETFsector.com Daily Trading Outlook

September 26, 2025 S&P futures a touch higher Friday morning after U.S. equities fell Thursday, with the S&P and Nasdaq down for a third straight session. Big tech, most-shorted, and tariff-exposed names led the pullback, while energy and select defensives outperformed. Asia closed mostly lower (South Korea, Taiwan, Hong Kong laggards), while Europe opened modestly

ETFsector.com Daily Trading Outlook Read More »

, , , , , , , , , , , , , , , , , , , , , ,

ETFsector.com Daily Trading Outlook

August 6, 2025 S&P futures +0.3%, following a quiet Tuesday where equities finished mostly lower on soft economic data. Tech lagged, while small caps, managed care, regional banks, airlines, and homebuilders outperformed. Overnight, Asian markets were mostly higher with Japan, China, Australia, and Singapore all posting gains. Europe is modestly green, up ~0.2%. Treasuries weaker,

ETFsector.com Daily Trading Outlook Read More »

, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

ETFsector.com Daily Trading Outlook

August 5, 2025 S&P futures up 0.1% following Monday’s sharp equity rally, which saw all major indexes gain over 1% and every sector finish higher except energy. Momentum, small caps, crypto, retail names, memes, and Mag 7 stocks led the charge. Overnight, Asian markets were mostly higher (led by South Korea and Taiwan), and Europe

ETFsector.com Daily Trading Outlook Read More »

, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

ETFsector.com Daily Trading Outlook

June 11, 2025 S&P 500 futures are down 0.1% following Tuesday’s gains that left the index less than 2% below its February record high. Most-shorted names continued to lead, alongside strength in big tech, energy, chemicals, builders, pharma, and transports. Asian equities rose overnight, with Hong Kong outperforming. European markets are up ~0.2%. Treasuries are

ETFsector.com Daily Trading Outlook Read More »

, , , , , , , , , , , , , , , , , , , , , , ,

ETFsector.com Daily Trading Outlook

May 6, 2025 S&P futures down 0.7% after U.S. equities ended mostly lower Monday, with the S&P 500 snapping a 9-day win streak. Mag 7 stocks, energy, media, and MedTech lagged, while airlines and retail/apparel names outperformed. Asian markets were mixed (Greater China led; Japan and South Korea closed), and Europe opened ~0.7% lower. Treasuries

ETFsector.com Daily Trading Outlook Read More »

, , , , , , , , , , , , , ,

ETFsector.com Daily Trading Outlook, December 20, 2024

S&P futures are down 0.8% Friday morning following Thursday’s mostly lower finish. The Dow managed a small gain, breaking a 10-day losing streak, while semis and homebuilders underperformed. Big tech was mostly higher. Treasuries firmed with a bull steepening curve, though rates remain higher for the week. The dollar is down 0.2%, gold up 0.3%,

ETFsector.com Daily Trading Outlook, December 20, 2024 Read More »

, , , , , , , , , , , , , , , ,

National Bank of Canada FI holds a stock position worth $107.20 million in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

National Bank of Canada FI increased its ownership in Vertex Pharmaceuticals Incorporated by 125.0% during the third quarter as reported in its latest Form 13F filing.

National Bank of Canada FI holds a stock position worth $107.20 million in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Read More »

, ,

Vertex presented the Phase 3 clinical data of the Vanza Triple and new data on the long-term impact of TRIKAFTA at the North American Cystic Fibrosis Conference.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has announced the initial acceptance of medical presentations regarding the Phase 3 data for the investigational once daily vanzacaftor/tezacaftor/deutivacaftor.

Vertex presented the Phase 3 clinical data of the Vanza Triple and new data on the long-term impact of TRIKAFTA at the North American Cystic Fibrosis Conference. Read More »

Scroll to Top

Subscribe to our Newsletter

Stay updated with the latests analysis and insights fromm etfsector.com

If you haven’t received your newsletter email, check your spam/junk folder and add us to your contacts to ensure delivery.